JULIO CESAR DE OLIVEIRA

Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 26
  • bookPart
    Risco cardíaco
    (2017) OLIVEIRA, Júlio César de
  • bookPart
    Risco de endocardite infecciosa
    (2015) OLIVEIRA, Júlio César de
  • article 1 Citação(ões) na Scopus
    External validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population
    (2021) LAZAR NETO, Felippe; MENDES, Thiago Bosco; MATOS, Paulo Marcelo Pontes Gomes; OLIVEIRA, Julio Cesar de; FAVARATO, Maria Helena Sampaio; LIN, Chin An; MARTINS, Milton Arruda
    Aim: To investigate the external validity of recent antihyperglycaemic trials evaluating cardiovascular outcomes in a multimorbid population. Materials and Methods: Selection criteria of 15 randomized controlled trials from the 2020 American Diabetes Association Standard of Care statement were applied in a stepwise manner to tertiary care patients with type 2 diabetes. Primary outcomes were the number of patients eligible per individual trial and for the aggregate of trials. Secondary outcomes included patient predictors of trial eligibility. Results: Of 1059 patients, the mean (SD) age was 66 (10.74) years, the median (IQR) Charlson index was 2 (2, 3) and 458 (43%) had documented cardiovascular disease. The median (IQR) number of patients included in individual trials was 263 (174.25-308.75) and 795 (75.1%) of them were eligible for at least one trial. Among those 264 ineligible, 127 (48.1%) had an HbA1c level of 7% or less and no cardiovascular disease; 53.5% and 34.4% of the patients were eligible for two and three different classes of drugs, respectively. The strongest predictor of trial eligibility was cardiovascular disease (risk ratio 2.17, 95% CI 2.01-2.35). Conclusions: A considerable proportion of multimorbid patients would be eligible for recent antihyperglycaemic trials. This positive finding can be attributed to development guidance in diabetes trials and the different approach we took, in which we evaluated inclusion by trials as an aggregate.
  • bookPart
    Avaliação e controle perioperatório do paciente diabético
    (2018) FAVARATO, Maria Helena; OLIVEIRA, Júlio César de
  • bookPart
    Uso e rotação de opioides
    (2023) FAVARATO, Maria Helena Sampaio; OLIVEIRA, Júlio César de; BRICOLA, Solange Aparecida Petilo de Carvalho
  • article 11 Citação(ões) na Scopus
    Comparative assessment of mortality risk factors between admission and follow-up models among patients hospitalized with COVID-19
    (2021) LAZAR NETO, Felippe; SALZSTEIN, Guilherme A.; CORTEZ, Andre L.; BASTOS, Thais L.; BAPTISTA, Fabiola V. D.; MOREIRA, Joanne A.; LAUTERBACH, Gerhard P.; OLIVEIRA, Julio Cesar de; ASSIS, Fabio C. de; AGUIAR, Marilia R. A.; DEUS, Aline A. de; DIAS, Marcos Felipe D. S.; SOUSA, Felipe C. B.; DUAILIBI, Daniel F.; KONDO, Rodrigo H.; MORAES, Augusto Cesar F. de; MARTINS, Milton A.
    Objectives: This study aimed to compare differences in mortality risk factors between admission and follow-up incorporated models. Methods: A retrospective cohort study of 524 patients with confirmed COVID-19 infection admitted to a tertiary medical center in S?o Paulo, Brazil from 13 March to 30 April 2020. Data were collected on admission, and the third, eighth and fourteenth days of hospitalization. The hazard ratio (HR) was calculated and 28-day in-hospital mortality risk factors were compared between admission and followup models using a time-dependent Cox regression model. Results: Of 524 patients, 50.4% needed mechanical ventilation. The 28-day mortality rate was 32.8%. Compared with follow-up, admission models under-estimated the mortality HR for peripheral oxygen saturation 92% (1.21 versus 2.09), heart rate 100 bpm (1.19 versus 2.04), respiratory rate >24/min (1.01 versus 1.82) and mechanical ventilation (1.92 versus 12.93). Low oxygen saturation, higher oxygen support and more biomarkers?including lactate dehydrogenase, C-reactive protein, neutrophillymphocyte ratio, and urea remained associated with mortality after adjustment for clinical factors at follow-up compared with only urea and oxygen support at admission. Conclusions: The inclusion of follow-up measurements changed mortality hazards of clinical signs and biomarkers. Low oxygen saturation, higher oxygen support, lactate dehydrogenase, C-reactive protein, neutrophil-lymphocyte ratio, and urea could help with prognosis of patients during follow-up. ? 2021 The Authors.
  • bookPart
    Avaliação pré-operatória
    (2023) FAINTUCH, Jacob Jehuda; OLIVEIRA, Júlio Cesar de
  • bookPart
    Prefácio da 3ª edição
    (2023) FAVARATO, Maria Helena Sampaio; SAAD, Rafael; IVANOVIC, Lígia Fidelis; JORGE, Maria Cecília Pavanel; OLIVEIRA, Júlio César de; SANTOS, Valter Garcia; MORINAGA, Christian Valle; BRICOLA, Solange Aparecida Petilo de Carvalho; NUNES, Maria do Patrocínio Tenório; MARTINS, Mílton de Arruda
  • bookPart
    Avaliação inicial
    (2017) OLIVEIRA, Júlio César de; IVANOVIC, Ligia Fidelis
  • bookPart
    Risco cardíaco
    (2023) OLIVEIRA, Júlio César de